London: Jazz Pharmaceuticals said on Thursday that its experimental drug to treat a neurological conditions which causes involuntary and rhythmic vibrations, failing to accomplish the main goal Mid-stage study,

Jazz shares fell nearly 4 percent to $108 in premarket trading.

Although patients treated with this drug showed improvement, SuvacaltamideThe company said these figures were not statistically significant.

Jazz said it will further evaluate the data from the study.

It is testing the drug in a separate study as a possible treatment for tremors associated with Parkinson’s disease. (Reporting by Mariam Sunny and Bhanavi Satija in Bengaluru; Editing by Mrigank Dhaniwala)